Vascular access perfectly reproduces myointimal hyperplasia that can be found in coronary or peripheral arteries and has a major advantage that these other sites cannot match: it is quite superficial and not close to a major vital organ and also affects a population that will attend the hospital for dialysis on a very regular basis. It therefore appears obvious to try and develop a tool that will mitigate myointimal hyperplasia and that could later be tested on coronary or peripheral arteries. Over the past few years several trials have been organized and we are now at a stage where some results have become available.
Roy-ChaudhuryP., KellyB.S., NarayanaA.. Hemodialysis vascular access dysfunction from basic biology to clinical intervention.Adv Ren Replace Ther.2002; 9: 74–84.
2.
Roy-ChaudhuryP., KellyB.S., MelhemM.. Novel therapies for hemodialysis vascular access dysfunction: fact or fiction!Blood Purif.2005; 23: 29–35.
3.
ChemlaE., MorsyM.Randomized clinical trial comparing decellularized bovine ureter with expanded polytetrafluoroethylene for vascular access.Br J Surg.2009; 96: 34–39.
4.
DemberL.M., BeckG.J., AllonM.. Dialysis Access Consortium Study Group Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.JAMA.2008; 299: 2164–2171.
5.
KatzmanH.E., McLaffertyR.B., RossJ.R., GlickmanM.H., PedenE.K., LawsonJ.H.Initial experience and outcome of a new hemodialysis access device for catheter-dependent patients.J Vasc Surg.2009; 50: 600–607.
6.
JahromeO.K., HoeferI., HoustonG.J.. Hemodynamic effects of spiral ePTFE prosthesis compared with standard arteriovenous graft in a carotid to jugular vein porcine model.J Vasc Access2011; 12(3): 224–230.
